Popular, Pharmaceutical Industry, Health Canada

Health Canada Consults on Pathway for Health Products Containing CBD

Stikeman Elliott LLP on 3/10/2025

Health Canada recently announced that it is exploring a regulatory pathway that would allow products containing cannabidiol (“CBD”) to be purchased without a prescription. Under the current regulatory scheme, all health...more

2024 mid-year highlights in Canadian life sciences IP and regulatory law

Smart & Biggar on 7/10/2024

In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories from January to June and...more

2022 Highlights in Canadian Life Sciences IP and Regulatory Law

Smart & Biggar on 1/5/2023

Below are highlights from the Rx IP’s team’s 2022 updates (see also our Top 10 Rx IP Update Reads of 2022): Contents: 1. Patent decisions on the merits 2. PMNOC Regulations: Fifth-year anniversary of major amendments,...more

2022 mid-year highlights in Canadian life sciences IP and regulatory law

Smart & Biggar on 7/25/2022

In the first half of 2022, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories from January to July and...more

Federal Court upholds Health Canada’s strict interpretation of patent listing deadline for KEYTRUDA formulation patent

Smart & Biggar on 4/28/2021

Update: Merck’s appeal was dismissed. The Federal Court recently dismissed Merck’s application for judicial review of Health Canada’s refusal to add Canadian Patent No. 2,830,806 (806 Patent) to the Patent Register, holding...more

New CADTH Report on Health Technology Trends in 2021

Smart & Biggar on 3/30/2021

The Canadian Agency for Drugs and Technologies in Health (CADTH) published an interesting new report on January 29, 2021 about Health Technology Trends to Watch. The report identifies the following list of emerging trends...more

2020 Highlights in Canadian Life Sciences IP and Regulatory Law

Smart & Biggar on 1/5/2021

In 2020, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. We review top developments below: Table of Contents 1. COVID-19: CIPO, Federal Courts, Health Canada 2. PMPRB:...more

Update on biosimilars in Canada – August 2020

Smart & Biggar on 8/27/2020

The following provides an overview of the many developments regarding biosimilars in Canada (approvals, pending submissions, regulatory, litigation and market access) that have taken place since our last update in October...more

2019 Highlights in Canadian Life Sciences IP and Regulatory Law

Smart & Biggar on 1/10/2020

In 2019, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. We review top developments below: 1) PMPRB: Amendments to Regulations will come into force July 1, 2020, court...more

Project Orbis enables concurrent regulatory approval of LENVIMA and KEYTRUDA combination therapy in Canada, U.S. and Australia

Smart & Biggar on 11/8/2019

On September 17, 2019, the combination therapy of Eisai’s LENVIMA (lenvatinib) and Merck’s KEYTRUDA (pembrolizumab) for the treatment of advanced endometrial carcinoma received simultaneous approvals by Health Canada, the...more

Today's Popular Updates › Pharmaceutical Industry › Health Canada

"My best business intelligence, in one easy email…"